This review covers experimental and clinical experiences with transpla
ntation of allogeneic veins processed by slow rate cooling with 2.5% (
WN) chondroitin sulfate and 1 M dimethylsulfoxide. These results are c
ontrasted with the results obtained using dimethylsulfoxide alone. The
short-term patency of experimental autologous (100%) and allogeneic (
7-100%) cryopreserved veins may be attributed to the combination of ''
no-touch'' procurement techniques employing the smooth muscle relaxant
papaverine, the chondroitin sulfate preservation method, and recipien
t therapy. Explanted autografts retain many cell and tissue functions.
In contrast, explanted allografts demonstrate short-term loss of endo
thelial cells and smooth muscle function, both of which subsequently r
eturn. Clinically there have been positive short-term correlations bet
ween good initial runoff from the graft site and 1-year patency (68-74
%) and limb salvage (94%) rates. In contrast, grafts with poor initial
runoff, composite grafts, or grafts requiring secondary reconstructio
n resulted in lower 1-year patency (40-44%) and limb salvage (64%) rat
es. More experience, larger study groups, and longer follow-up are nec
essary to evaluate the clinical performance of chondroitin sulfate-pre
served grafts. In the meantime, chondroitin sulfate-preserved veins ar
e reserved for coronary artery bypass or peripheral bypass patients in
the absence of suitable autologous vessels. (C) 1994 Academic Press,
Inc.